FAST update on the impact of Covid-19
While the world as we know it has changed, abruptly and dramatically, we at FAST want you to know that we are here and we continue to move forward in our mis
FAST funds pioneering infrastructure grant
FAST is thrilled to announce a grant to our continued partners and renowned scientists dedicated to advancing therapeutics for Angelman syndrome.
Bienvenue FAST France
FAST is proud to announce the newest addition to its global family: FAST France. Charlotte Prestat and Anthony Moisan, the founders of FAST France, have thre
Global Angelman Syndrome Registry moves platform to QUT
The Global Angelman Syndrome Registry (Registry) had some downtime this week while the platform was moved to the Division of Researc
Webinar on the KIK-AS Clinical Trials of GTX-102
Additional details on the clinical trials for GTX-102 are available at the link below: https://clinicaltrials.gov/ct2/show/NCT04259281 – A Study of
Webinar on GTX-102, an investigational antisense oligonucleotide for the treatment of Angelman syndrome
FAST thanks GeneTx Biotherapeutics and Dr. Scott Stromatt for offering insight on GTX-102, the investigational antisense oligonucleotide for the treatment of
Frequently asked questions regarding the GeneTx KIK-AS Clinical Trial
GeneTx Biotherapeutics has announced it has received IRB approval from Rush University Medical Center in Chicago, IL to begin the «KIK-AS» (Knockdown of UB
Live Stream of the Educational Tracks of the Global Science Summit
Join in today to watch the live stream of the educational tracks of the FAST Global Science Summit! Session A: AAC and Behavior Session B: Physical and Senso
Live Stream of Global Science Summit
Join in today to watch the live stream of the FAST Global Science Summit!
An interview with Dr. David Segal on the UC Davis center and the future of gene editing as therapy
Barb Bailus, PhD David Gurzick, PhD Hello Everyone! Today we have a very special guest with us, Dr. Dave Segal! He is joining us to discuss the amazing new n